HK1208805A1 - 用於治療癌症的β-水解酶抑制劑 - Google Patents
用於治療癌症的β-水解酶抑制劑 Download PDFInfo
- Publication number
- HK1208805A1 HK1208805A1 HK15109523.0A HK15109523A HK1208805A1 HK 1208805 A1 HK1208805 A1 HK 1208805A1 HK 15109523 A HK15109523 A HK 15109523A HK 1208805 A1 HK1208805 A1 HK 1208805A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methyl
- hydroxy
- acetoxy
- fluorophenyl
- furanon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261704014P | 2012-09-21 | 2012-09-21 | |
| US61/704,014 | 2012-09-21 | ||
| PCT/US2013/061050 WO2014047519A2 (en) | 2012-09-21 | 2013-09-20 | Inhibitors of beta-hydrolase for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208805A1 true HK1208805A1 (zh) | 2016-03-18 |
Family
ID=50342080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15109523.0A HK1208805A1 (zh) | 2012-09-21 | 2013-09-20 | 用於治療癌症的β-水解酶抑制劑 |
Country Status (10)
| Country | Link |
|---|---|
| US (8) | US9771356B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3345596B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6469009B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102137180B1 (cg-RX-API-DMAC10.html) |
| CN (2) | CN110818660B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2013317791B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2885762C (cg-RX-API-DMAC10.html) |
| ES (2) | ES2865412T3 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1208805A1 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2014047519A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3345596B1 (en) | 2012-09-21 | 2021-01-20 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
| WO2019012159A1 (en) * | 2017-07-14 | 2019-01-17 | Protea Biopharma N.V. | METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE |
| WO2019246093A1 (en) * | 2018-06-18 | 2019-12-26 | Midwestern University | Monoclonal antibodies targeting epitopes of asph |
| CN109364251A (zh) * | 2018-12-06 | 2019-02-22 | 苏州大学 | Tet蛋白在治疗抑郁症中的应用 |
| KR20210129115A (ko) * | 2019-02-15 | 2021-10-27 | 미드웨스턴 유니버시티 | 동위원소-안정화된 테트론이미드 화합물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE39717C (de) | H. LEHMANN in München, Enhuberstr. 5 part | Bleistifthalter | ||
| DD39717A (cg-RX-API-DMAC10.html) * | ||||
| JPS63500375A (ja) * | 1985-08-02 | 1988-02-12 | シエブロン リサ−チ カンパニ− | 除草性２−（オクサまたはチアヘテロサイクル）５−アミノ−３−オクソ−４−（置換−フェニル）−２、３−ジヒドロフラン類 |
| US5314913A (en) * | 1992-12-08 | 1994-05-24 | American Home Products Corporation | 4- or 5-(substituted sulfonyl)methyl-3(2H)-furanones |
| US5698585A (en) * | 1995-04-13 | 1997-12-16 | Kikkoman Corporation | Pharmaceutical preparation for prevention and/or treatment for cataract |
| JPH09110853A (ja) * | 1995-10-12 | 1997-04-28 | Kikkoman Corp | ４‐アシルオキシフラノン誘導体又はその塩及びその製造方法 |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| WO1998041516A1 (en) | 1997-03-14 | 1998-09-24 | Merck Frosst Canada & Co. | (methylsulfonyl)phenyl-2-(5h)-furanones with oxygen link as cox-2 inhibitors |
| US5877193A (en) * | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| US6835370B2 (en) | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
| US20050123545A1 (en) | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
| US20030031670A1 (en) | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| WO2003018575A1 (en) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase |
| US6667330B2 (en) * | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| AU2002950862A0 (en) | 2002-08-19 | 2002-09-12 | Biosignal Pty Ltd | Furanone derivatives and methods of making same |
| EP1554394B1 (en) | 2002-10-16 | 2009-12-16 | Isis Innovation Limited | Screening methods using a structural model of FIH |
| WO2005070916A1 (en) * | 2004-01-09 | 2005-08-04 | Eli Lilly And Company | Thiophene and furan compounds |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| EP2576532B1 (en) * | 2010-06-07 | 2018-07-18 | Novomedix, LLC | Furanyl compounds and the use thereof |
| EP3345596B1 (en) | 2012-09-21 | 2021-01-20 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
-
2013
- 2013-09-20 EP EP17202827.6A patent/EP3345596B1/en not_active Not-in-force
- 2013-09-20 EP EP13838498.7A patent/EP2897607B1/en not_active Not-in-force
- 2013-09-20 ES ES17202827T patent/ES2865412T3/es active Active
- 2013-09-20 HK HK15109523.0A patent/HK1208805A1/xx unknown
- 2013-09-20 CN CN201910949656.0A patent/CN110818660B/zh not_active Expired - Fee Related
- 2013-09-20 WO PCT/US2013/061050 patent/WO2014047519A2/en not_active Ceased
- 2013-09-20 AU AU2013317791A patent/AU2013317791B2/en not_active Ceased
- 2013-09-20 WO PCT/US2013/060934 patent/WO2014047447A2/en not_active Ceased
- 2013-09-20 ES ES13838498.7T patent/ES2660822T3/es active Active
- 2013-09-20 CN CN201380061004.4A patent/CN104902889A/zh active Pending
- 2013-09-20 JP JP2015533237A patent/JP6469009B2/ja not_active Expired - Fee Related
- 2013-09-20 KR KR1020157010188A patent/KR102137180B1/ko not_active Expired - Fee Related
- 2013-09-20 US US14/430,101 patent/US9771356B2/en active Active
- 2013-09-20 CA CA2885762A patent/CA2885762C/en active Active
-
2017
- 2017-07-17 US US15/651,842 patent/US10106532B2/en active Active
- 2017-09-26 US US15/715,989 patent/US10710995B2/en active Active
-
2018
- 2018-09-14 US US16/131,275 patent/US10351555B2/en active Active
-
2019
- 2019-06-12 US US16/439,253 patent/US10787445B2/en active Active
-
2020
- 2020-06-02 US US16/890,680 patent/US20200361925A1/en not_active Abandoned
- 2020-09-23 US US17/029,127 patent/US20210032233A1/en not_active Abandoned
-
2022
- 2022-04-14 US US17/720,472 patent/US20220251076A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101959404B (zh) | 单磷酸腺苷活化蛋白激酶调节剂 | |
| CN102424681B (zh) | 酰基四氢-β-咔啉类化合物及其衍生物、用途及其制备方法 | |
| US20220251076A1 (en) | Inhibitors of Beta-Hydoxylase for Treatment of Cancer | |
| JPWO2015083833A1 (ja) | 新規キナゾリン誘導体 | |
| WO2016034634A1 (fr) | Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak | |
| JP2023523036A (ja) | Ｌｏｘ酵素阻害方法及び組成物 | |
| US11897857B2 (en) | Isotopically-stabilized tetronimide compounds | |
| WO2019196780A1 (zh) | 一种新型吲哚胺2，3-双加氧酶抑制剂及其制备方法和用途 |